Fineline Cube

Follow:
14855 Articles
*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal
CompanyDeals

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China
CompanyDeals

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

InventisBio's Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16
CompanyDrug

InventisBio’s Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

Nuance Pharma Doses First Participant in REACH Phase III Trial of STG320 for House Dust Mite Allergic Rhinitis in China
CompanyDrug

Nuance Pharma Doses First Participant in REACH Phase III Trial of STG320 for House Dust Mite Allergic Rhinitis in China

Sanofi's Q3 Net Revenue Climbs 14.3% to EUR 14.44 Billion as Dupixent Sales Surge 34.8% to a Record EUR 5.69 Billion
Company

Sanofi’s Q3 Net Revenue Climbs 14.3% to EUR 14.44 Billion as Dupixent Sales Surge 34.8% to a Record EUR 5.69 Billion

Dizal Pharmaceutical Reports First‑Ever Profit as AstraZeneca's USD 600 Million Sunvozertinib Deal Drives 714% Revenue Surge
Company

Dizal Pharmaceutical Reports First‑Ever Profit as AstraZeneca’s USD 600 Million Sunvozertinib Deal Drives 714% Revenue Surge

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer
CompanyDrug

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease
CompanyDrug

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Eli Lilly's Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes
CompanyDrug

Eli Lilly’s Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

HutchMed's Sovleplenib Granted FDA Orphan Drug Designation for Primary Immune Thrombocytopenia – Selective Syk Inhibitor Broadens Global Regulatory Footprint
CompanyDrug

HutchMed’s Sovleplenib Granted FDA Orphan Drug Designation for Primary Immune Thrombocytopenia – Selective Syk Inhibitor Broadens Global Regulatory Footprint

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties
CompanyDeals

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Hengrui Secures Dual NMPA Clinical Trial Approvals – KAT6 Inhibitor HRS-2189 Advances in Prostate Cancer, HRS-8046 Targets KRAS G12D Solid Tumors
CompanyDrug

Hengrui Secures Dual NMPA Clinical Trial Approvals – KAT6 Inhibitor HRS-2189 Advances in Prostate Cancer, HRS-8046 Targets KRAS G12D Solid Tumors